Full history for every metric is available with a Kvantra account
PharmaSGP Holding SE (PSG.DE)
Key financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 63 | 63 | 65 | 86 | 101 | 119 | 122 |
| Operating profit | €m | 28 | 28 | |||||
| Net profit | €m | 17 | 11 | 11 | 12 | 16 | 20 | 20 |
| EPS reported | € | 1.65 | 1.67 | |||||
| Operating cashflow per share | € | 2.09 | 2.09 | |||||
| Capex per share | € | 0.12 | 0.12 | |||||
| FCF per share | € | 1.97 | 1.97 | |||||
| Free cash flow | €m | 23 | 21 | |||||
| Net debt | €m | -26 | -29 | |||||
| Book value equity | €m | 32 | 37 | |||||
| Book value per share | € | 2.69 | 3.18 | |||||
| Number of shares | m | 11.87 | 11.54 | |||||
| DPS (TTM paid) | € | 0.05 | 0.00 |
Financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 15.15 | - | |||||
| P/B LTM | x | 9.29 | 9.11 | |||||
| P/S LTM | x | 2.50 | 2.73 | |||||
| P/FCF LTM | x | 12.68 | 16.17 | |||||
| EV/EBITDA LTM | x | 6.85 | 7.72 | |||||
| EV/Sales LTM | x | 2.28 | 2.49 | |||||
| Earnings Yield LTM | % | 6.60% | 5.67% | |||||
| FCF Yield | % | 7.88% | 6.18% | |||||
| Quality | ||||||||
| ROE | % | 61.12% | 54.48% | |||||
| ROIC | % | 22.61% | 22.61% | |||||
| Operating margin | % | 23.26% | 23.26% | |||||
| Gross margin | % | 90.87% | 90.87% | |||||
| FCF/Sales | % | 19.69% | 19.69% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +20.44% | +9.87% | |||||
| Sales Growth YoY | % | +17.55% | +13.80% | |||||
| Net Income Growth YoY | % | +19.14% | +8.81% | |||||
| FCF Growth | % | -9.19% | -14.83% | |||||
| Operating Profit Growth | % | +12.18% | +2.35% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 5.49% | 0.00% | |||||
| Dividend Growth | % | -96.32% | - | |||||
| Payout Ratio | % | 83.48% | 82.81% | |||||
| FCF/Debt | x | 24.30 | 24.01 | |||||
| Net Debt/EBITDA | x | -0.64 | -0.64 | |||||
| EBIT/Net interest | x | 6.31 | 6.31 | |||||
| Net debt/market cap | % | -8.92% | -8.78% | |||||
| Net debt/Equity | x | -0.83 | -0.80 | |||||
| Gross debt/equity | x | 0.03 | 0.02 | |||||
Company overview
Founded in 2012 and based in Gräfelfing, Germany, PharmaSGP Holding SE specializes in the production of over-the-counter (OTC) pharmaceuticals and diverse healthcare goods. The company offers an extensive portfolio of products addressing various health concerns. This includes Baldriparan for sleep disturbances; pain relief solutions like Spalt, Formigran, and Kamol massage cream; RubaXX, specifically designed for rheumatic pain in bones, tendons, and muscles; and Restaxil, which targets nerve pain in the neck and back. Furthermore, their offerings encompass Fulminan, a beauty beverage for areas such as the eyes, buttocks, and thighs; DESEO drops for sexual weakness; Neradin, a medication for sexual dysfunction; and TAUMEA, aimed at managing vertigo. PharmaSGP also develops treatments for chronic conditions, including persistent pain and other age-associated ailments. Its products reach consumers via pharmacies and wholesalers, and are exported to several European nations, including Austria, Italy, Belgium, Spain, and France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PharmaSGP Holding SE (PSG.DE)
Founded in 2012 and based in Gräfelfing, Germany, PharmaSGP Holding SE specializes in the production of over-the-counter (OTC) pharmaceuticals and diverse healthcare goods. The company offers an extensive portfolio of products addressing various health concerns. This includes Baldriparan for sleep disturbances; pain relief solutions like Spalt, Formigran, and Kamol massage cream; RubaXX, specifically designed for rheumatic pain in bones, tendons, and muscles; and Restaxil, which targets nerve pain in the neck and back. Furthermore, their offerings encompass Fulminan, a beauty beverage for areas such as the eyes, buttocks, and thighs; DESEO drops for sexual weakness; Neradin, a medication for sexual dysfunction; and TAUMEA, aimed at managing vertigo. PharmaSGP also develops treatments for chronic conditions, including persistent pain and other age-associated ailments. Its products reach consumers via pharmacies and wholesalers, and are exported to several European nations, including Austria, Italy, Belgium, Spain, and France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free